CPT1A and cancer: We firstly examined the proper concentrations of tamoxifen/fulvestrant and CPT1 inhibitor etomoxir for their combinatory treatment by using different doses, we found that combining fulvestrant with etomoxir showed synergistic effect on inhibiting endocrine-resistant cancer cell growth in a dose-dependent manner (Supplementary Figures 5A–F).